title: Selective induction of mucosal immune responses to 2-acetylaminofluorene.
abstract: Mucosal vaccination with chemical carcinogens coupled to enterotoxins such as cholera toxin (CT) can elicit carcinogen-specific immunoglobulin secretion into the intestinal lumen. The present study examines the ability of several related bacterial enterotoxins and their subunits to act as adjuvants or carrier proteins in stimulating an intestinal secretory IgA (S-IgA) response to 2-acetylaminofluorene (AAF). Using Thiry-Vella loops in rabbits, CT, cholera toxin B subunit (CTB) and the recombinant B subunit of the heat labile enterotoxin from E. coli (rLTB) were all found to be effective carrier proteins and adjuvants for eliciting S-IgA anti-AAF. However, marked differences in the ratio of mucosal S-IgA to serum IgG production were observed. CT elicited the highest luminal S-IgA anti-AAF titers as well as the highest ratio of intestinal S-IgA/serum IgG when used as an adjuvant. Conversely, rLTB elicited a high serum IgG anti-AAF titer but only a modest intestinal S-IgA response. Dialysis studies using monoclonal IgA versus IgG anti-AAF on opposing sides of a semipermeable membrane demonstrated the potential importance of the intestinal S-IgA/serum IgG ratio. A high "intestinal" IgA/"serum" IgG ratio abolished carcinogen transfer to the "serum" side of the membrane, while a low ratio enhanced transfer. Thus, to generate an active mucosal immune response capable of blocking carcinogen absorption, the carrier protein or adjuvant should be selected to optimize the intestinal S-IgA/serum IgG ratio.
authors.affiliation: University of Connecticut, Center for Environmental Health, Storrs 06269, USA.
authors.forename: L K
authors.initials: LK
authors.lastname: Silbart
authors.forename: F
authors.initials: F
authors.lastname: McAleer
authors.forename: M V
authors.initials: MV
authors.lastname: Rasmussen
authors.forename: L
authors.initials: L
authors.lastname: Goslinoski
authors.forename: D F
authors.initials: DF
authors.lastname: Keren
authors.forename: A
authors.initials: A
authors.lastname: Finley
authors.forename: H J
authors.initials: HJ
authors.lastname: Van Kruiningen
authors.forename: J M
authors.initials: JM
authors.lastname: Winchell
mesh_terms: D015073:2-Acetylaminofluorene / Q000276:immunology* / Q000378:metabolism; D000276:Adjuvants, Immunologic / Q000378:metabolism; D000818:Animals; D000906:Antibodies / Q000097:blood*; D002273:Carcinogens / Q000378:metabolism; D002352:Carrier Proteins / Q000276:immunology* / Q000378:metabolism; D004768:Enterotoxins / Q000276:immunology* / Q000378:metabolism; D005260:Female; D007071:Immunoglobulin A, Secretory / Q000378:metabolism*; D007074:Immunoglobulin G / Q000097:blood*; D007413:Intestinal Mucosa / Q000276:immunology* / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D013047:Specific Pathogen-Free Organisms
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D002273:Carcinogens; D002352:Carrier Proteins; D004768:Enterotoxins; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D015073:2-Acetylaminofluorene